Research Article Details
| Article ID: | A00918 |
| PMID: | 34929996 |
| Source: | Minerva Gastroenterol (Torino) |
| Title: | Evaluation of MACK-3 parameters, metabolic and fibrotic characteristics of non-alcoholic fatty liver disease patients with hypertension. |
| Abstract: | BACKGROUND: Non-alcoholic steatohepatitis (NASH) is an inflammatory subtype of non-alcoholic fatty liver disease (NAFLD) and recent non-invasive test, MACK-3, demonstrated good diagnostic characteristics for fibrosis in a number of studies. The aim of our study was to assess the liver state using the non-invasive MACK-3 test, and its link with liver fibrosis stage, inflammatory activity, steatosis and metabolic markers in NAFLD patients with hypertension (HT). METHODS: Thirty adult NAFLD patients with HT, aged 30 to 60 years (mean age (46.36 ± 5.1) years) were included in our study. The control group consisted of 20 healthy volunteers. In addition to basic laboratory tests and ultrasonographic examination, validated non-invasive fibrosis test were performed. MACK-3 was calculated using the online calculator with the following variables: fasting glucose, fasting insulin, aspartate aminotransferase (AST) and cytokeratin 18 (CK18). RESULTS: All NAFLD patients with HT were characterized with increased liver enzymatic activity, lipid profile, increased levels of insulin and HOMAIR (˂ 0.001). MACK-3 parameters were positively correlated with thymol test - direct link - r = 0.45 (p <0.013), with aspartataminotransferase (AST) r = 0.38 (p <0.03) and alanineaminotransferase (ALT) - r = 0.38 (p<0.03), with the stage of Fibrotest activity r = 0.25 (p <0.018) and steatosis r = 0.76 (p <0.001). CONCLUSIONS: MACK-3 parameters associations with hepatic enzymatic activity, steatosis and activity stage suggest this test as a promising for screening use in such patients and requires further studies. |
| DOI: | 10.23736/S2724-5985.21.02982-X |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I12 | 10763 | Hypertension | An artery disease characterized by chronic elevated blood pressure in the arteries. https://en.wikipedia.org/wiki/Hypertension, https://www.ncbi.nlm.nih.gov/pubmed/24352797 | disease of anatomical entity/ cardiovascular system disease/vascular disease/ artery disease | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |